Unlock instant, AI-driven research and patent intelligence for your innovation.

Modulators of cellular adhesion

An aliphatic, compound technology, used in organic chemistry, organic active ingredients, medical preparations containing active ingredients, etc.

Active Publication Date: 2007-01-24
NOVARTIS PHARM AG
View PDF19 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

All of these molecules appear to act non-specifically, either by inhibiting the transcription of ICAM-1 as well as other proteins, or acting intramolecularly to inhibit leukocyte integrin activation by unknown mechanisms, and none appear to directly antagonize the association of CAM with Interaction of leukocyte integrins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modulators of cellular adhesion
  • Modulators of cellular adhesion
  • Modulators of cellular adhesion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0405] This example describes the synthesis of the following compounds

[0406]

[0407] It was prepared according to Scheme 1A and the following procedure.

[0408] Diagram 1A

[0409]

[0410] a) A solution of 3-methoxyphenylethylamine (0.2 mol) and formaldehyde (0.22 mol) in aqueous HCl (20%, 500 mL) was heated at 80°C for 4 hours. The reaction was then concentrated to dryness, and the residue was dissolved in hydrobromic acid (40% in water, 500 mL) and refluxed for 24 hours. The reaction was concentrated to give a brown solid which was used without purification. Water (200 mL) and tetrahydrofuran ("THF") (300 mL) were added to the residue and sodium carbonate (solid, 0.5 mol) was added very carefully to the resulting mixture, followed by di-tert-butyl dicarbonate (0.3 mol) . After 15 hours at room temperature, the reaction was extracted with ethyl acetate (1 L), and the organic extract was washed with saturated potassium dihydrogen phosphate and brine, dried over...

Embodiment 2

[0427] This example describes the synthesis of the following compounds,

[0428]

[0429] It was prepared according to the procedure of Example 1g except that 4-chlorobenzoic acid was used instead of compound 1.11. 1 H NMR (400MHz, CD 3 OD): δ7.64(m, 2H), 7.35-7.49(m, 5H), 7.11(s, 1H), 4.98(t, J=8.0Hz, 1H), 4.63 and .88(m, 2H), 3.83 (d, J = 8.0 Hz, 2H), 3.68 and 3.98 (m, 2H), 2.89 (m, 2H) ppm; ESI-MS (m / z): (M+1) 579.90.

Embodiment 3

[0431] This example describes the synthesis of the following compounds,

[0432]

[0433] It was prepared according to Scheme 2 and the following procedure.

[0434] Diagram 2

[0435]

[0436] a) To 10 mmol of commercially available 3.1 in 20 mL of MeOH and 20 mL of CH at 0 °C 2 Cl 2 Slowly add 20 mmol of 2.0M TMSCHN in hexane to the solution in 2 , and the resulting mixture was stirred at room temperature for 30 minutes. The solvent was removed and the residue was dried in vacuo to give crude 3.2.

[0437] b) Then, compound 3.2 and 15 mmol of isopropyl azide in 0.2 mmol of CuI, 0.2 mmol of Et 3 In the presence of N in 50 mL of CH 3 CN was stirred overnight at room temperature. The solvent was removed and the residue was purified by column chromatography to give compound 3.3 in 55% yield. ESI-MS (m / z): (M+1) 313.20.

[0438] c) A mixture of 2 mmol of compound 3.3 in 10 mL of 4.0N HCl in dioxane was stirred at room temperature for 12 hours. The solvent was remo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR<1> are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11 / CD18 family of cellular adhesion molecules (e.g., LFA-1).

Description

[0001] priority [0002] This application claims priority to US Provisional Applications 60 / 560,517, filed April 8, 2004, and 60 / 517,535, filed November 5, 2003, the entire contents of which are incorporated herein by reference. Background of the invention [0003] Research conducted over the past decade has helped to elucidate the molecular events involved in cell-cell interactions in vivo, especially those involved in the movement and activation of cells in the immune system. See generally Springer, T. Nature, 1990, 346, 425-434. Cell surface proteins, particularly cell adhesion molecules ("CAM") and "leukointegrins", including LFA-1, MAC-1, and gp150.95 (referred to as CD18 / CD11a, CD18 / CD11b, and CD18 / CD11c) has accordingly been the subject of drug development aimed at intervening in the process of leukocyte extravasation into the lesion and leukocyte migration to different targets. For example, activation of integrins constitutively expressed on leukocytes, followed by i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D409/12C07D407/14C07D401/12C07D409/06C07D403/14C07D409/14A61K31/4725
Inventor 沈旺肯尼斯·巴尔约翰·D·欧斯洛博钟民
Owner NOVARTIS PHARM AG